Complete Dosing Schedules & UK Availability Comparison
Wegovy vs Mounjaro Dose Comparison: Current UK Stock Status
The most significant advantage for UK patients considering either treatment is immediate availability. EverydayMeds maintains comprehensive stock levels of all Wegovy doses (0.25mg through 2.4mg) and Mounjaro options, eliminating the supply uncertainties that have historically affected semaglutide availability. This wegovy mounjaro dose comparison reveals that both follow structured escalation protocols, but with different timelines and mechanisms.
Wegovy follows a precise 16-week escalation schedule: starting at 0.25mg weekly for four weeks, progressing through 0.5mg, 1mg, and 1.7mg phases before reaching the 2.4mg maintenance dose. Mounjaro begins at 2.5mg weekly and escalates more gradually over 12 weeks to its maintenance doses. Both treatments require prescription-only medicine status and clinical oversight throughout the dose adjustment period, ensuring patient safety whilst optimising therapeutic outcomes.
Wegovy Mounjaro Dose Comparison: Pricing Structure Analysis
Our wegovy mounjaro dose comparison pricing reflects the different escalation requirements for each treatment. Wegovy single pen prices begin at £79.99 for the 0.25mg starter dose, progressing to £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), and £209.99 for the 2.4mg maintenance dose. New customers apply discount code FIRST40 at checkout, whilst returning patients use DOSE25 to access these competitive rates.
Bundle options provide convenience for patients planning their treatment journey. The Intro Trio (0.25mg, 0.5mg, 1mg) costs £299.99, covering the first 12 weeks of treatment in a single order. The Ultimate Stability Trio offers three months of 2.4mg maintenance supply for £649.99. These bundles ensure uninterrupted treatment progression whilst reducing the frequency of reordering, particularly valuable given the importance of consistent dosing schedules in both treatment protocols.
Clinical Evidence in Wegovy Mounjaro Dose Comparison Studies
The STEP clinical trial programme demonstrated that patients taking Wegovy alongside diet and exercise achieved an average of ~clinically studied weight loss at 68 weeks (Wilding et al., NEJM, 2021). The dose escalation protocol proved crucial for tolerability, with the gradual increase from 0.25mg to 2.4mg allowing patients to adapt to the medication's effects. These results informed current wegovy mounjaro dose comparison guidelines used by prescribers.
Mounjaro's SURMOUNT trials showed comparable efficacy with its tirzepatide formulation, though direct head-to-head wegovy mounjaro dose comparison studies have not been conducted due to different trial designs and patient populations. Both treatments work through appetite regulation mechanisms, with Wegovy targeting GLP-1 receptors specifically whilst Mounjaro activates both GIP and GLP-1 pathways. Clinical outcomes depend on individual patient response, adherence to prescribed dosing schedules, and lifestyle modifications.
How Wegovy Works: Mechanism Behind the Dosing Schedule
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics a natural hormone responsible for regulating appetite and blood sugar levels. The medication works by slowing gastric emptying, promoting feelings of satiety after smaller meals, and potentially reducing food cravings through effects on brain appetite centres. The gradual dose escalation from 0.25mg to 2.4mg allows patients to adapt to these physiological changes whilst minimising gastrointestinal side effects. This careful wegovy mounjaro dose comparison consideration explains why the 16-week escalation schedule cannot be accelerated or modified. Each dose level serves a specific purpose in building tolerance whilst maintaining therapeutic effectiveness throughout the weight management journey.
Ordering Process for Wegovy Mounjaro Dose Comparison Options
EverydayMeds streamlines access to both treatments through our comprehensive online service, making this wegovy mounjaro dose comparison practical rather than theoretical. The process begins with a 3-minute clinical assessment covering medical history, current medications, and weight management goals. Our prescribers review applications within 3 working days (24-hour express service available), determining the most appropriate treatment and starting dose based on individual circumstances. Once approved, both Wegovy and Mounjaro ship via next-day cold-chain delivery, maintaining the 2-8°C temperature requirements throughout transit. This efficient process ensures patients can begin their chosen treatment without unnecessary delays, supported by our GPhC-registered pharmacy credentials (#9012878).
Storage Advantages in Wegovy Mounjaro Dose Comparison
A practical advantage emerges in this wegovy mounjaro dose comparison regarding storage flexibility. Wegovy pens maintain stability for up to 6 weeks at room temperature (below 30°C) once removed from refrigeration, compared to Mounjaro's 21-day limit. This difference proves particularly valuable for frequent travellers or those with unpredictable schedules, as Wegovy offers greater flexibility without compromising medication integrity. Both treatments use pre-filled injection pens with dose counters, but Wegovy's FlexTouch technology provides tactile and auditory feedback during injection. The weekly injection schedule remains consistent for both options, though the specific dose escalation timelines differ as outlined in their respective treatment protocols.
Wegovy Mounjaro Dose Comparison: Supply Chain Reliability
Historical supply shortages have made medication availability a primary concern for patients considering GLP-1 treatments. EverydayMeds addresses this challenge through diversified supply relationships and proactive stock management, ensuring both options in our wegovy mounjaro dose comparison remain consistently available. Our direct partnership with Novo Nordisk for Wegovy supply provides early visibility into allocation schedules, whilst our Mounjaro inventory reflects strong distributor relationships within the UK pharmaceutical network.
This reliability extends to our inventory management across all dose strengths, preventing the common scenario where patients reach their escalation milestone only to find their next dose unavailable. Both treatments require uninterrupted dosing schedules for optimal effectiveness, making supplier reliability a clinical as well as practical consideration. Our stock monitoring systems track usage patterns and anticipate demand, ensuring that both options in this wegovy mounjaro dose comparison remain accessible when patients need them most.
Clinical Decision Support for Wegovy Mounjaro Dose Comparison
The choice between these treatments depends on individual patient factors that extend beyond simple wegovy mounjaro dose comparison charts. Our prescribers evaluate medical history, current medications, lifestyle factors, and treatment preferences when recommending between semaglutide and tirzepatide options. Both Wegovy and Mounjaro are available from EverydayMeds — your prescriber can help determine which is right for you based on comprehensive clinical assessment rather than generalised comparisons. Factors such as injection frequency tolerance, storage requirements, previous GLP-1 experience, and specific weight management goals all influence the optimal treatment selection. Our clinical team provides ongoing support throughout the dose escalation period, ensuring patients understand their chosen treatment protocol whilst monitoring for effectiveness and tolerability. This personalised approach recognises that successful weight management requires individualised treatment plans supported by expert clinical guidance and reliable medication supply.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
